Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia Published in the Journal Blood
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics plc (NASDAQ:AUTL) has announced the publication of data from its AUTO1/22 Phase 1 study in Pediatric B-cell Acute Lymphoblastic Leukemia in the journal Blood. The study was previously presented at the European Society for Blood and Marrow Transplantation in April.
September 05, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of the AUTO1/22 Phase 1 study data could potentially boost investor confidence in Autolus Therapeutics, as it indicates progress in their research and development efforts.
The publication of clinical trial data is a key milestone for biopharmaceutical companies. It indicates progress in their research and development efforts and can potentially attract more investors. Therefore, this news is highly relevant and important for Autolus Therapeutics and could potentially have a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100